It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

# <sup>1</sup>**Title: Multiple Introductions of Mpox virus to Ireland during the 2022 International**

- <sup>2</sup>**Outbreak**
- $\mathbf{R}$
- 4 **Authors:** Gabriel Gonzalez,<sup>1,2,3</sup> Michael Carr,<sup>1,3</sup> Tomás M. Kelleher,<sup>1</sup> Emer O'Byrne,<sup>1</sup>
- 5 Weronika Banka,<sup>1</sup> Brian Keogan,<sup>1</sup> Charlene Bennett,<sup>1</sup> Geraldine Franzoni,<sup>1</sup> Patrice Keane,<sup>4</sup>
- 6 Luke W. Meredith, <sup>8</sup> Nicola Fletcher, <sup>5,6</sup> Jose Maria Urtasun-Elizari, <sup>1</sup> Jonathan Dean, <sup>1</sup> Brendan
- 7 Crowley,<sup>4</sup> Derval Igoe,<sup>7</sup> Eve Robinson,<sup>7</sup> Greg Martin,<sup>7</sup> Jeff Connell,<sup>1</sup> Cillian F. De Gascun,<sup>1</sup>
- 8 Daniel Hare<sup>1</sup>
- 

## 10 **Affiliations**<br><sup>11</sup> UCD Nation

- <sup>1</sup> UCD National Virus Reference Laboratory, University College Dublin, Belfield, D04
- 12 E1W1, Ireland<br>13  $\frac{2}{1}$ Japan Initiativ
- <sup>2</sup> Japan Initiative for World-leading Vaccine Research and Development Centers, Hokkaido
- 14 University, Institute for Vaccine Research and Development, Hokkaido 001-0021, Japan<br>15 <sup>3</sup> International Collaboration Unit. International Institute for Zoonosis Control. Hokkaido
- $3$  International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido
- 16 University, Sapporo, Hokkaido 001-0020, Japan<br>17 <sup>4</sup> Department of Virology, St. James's Hospital, I
- <sup>4</sup> Department of Virology, St. James's Hospital, Dublin, Ireland
- <sup>5</sup> Veterinary Sciences Centre, University College Dublin, Belfield, D04 E1W1, Ireland
- <sup>6</sup> Centre for Experimental Pathogen Host Research, University College Dublin, Belfield, D04
- 20 E1W1, Ireland<br>21 <sup>7</sup> Health Protec
- 21  $\frac{7}{1}$  Health Protection Surveillance Centre, Ireland
- <sup>8</sup> Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- $23$
- <sup>24</sup>**Correspondence:** Daniel Hare (daniel.hare@ucd.ie)
- $25$

It is made available under a CC-BY 4.0 International license.

<sup>26</sup>**Abstract Background:** mpox (formerly Monkeypox) virus (MPXV) was considered a rare zoonotic 28 disease prior to May 2022, when a global epidemic of cases in non-endemic countries led to 29 the declaration of a Public Health Emergency of International Concern. Previously, mpox 30 infection was associated with symptoms similar to smallpox, although substantially less 31 severe, including fever, an extensive characteristic rash and swollen lymph nodes. 32 **Aim:** Elucidating the origin and molecular characteristics of the virus circulating in the<br>33 Republic of Ireland in the period between May and November 2022. 33 Republic of Ireland in the period between May and November 2022.<br>34 Methods: Whole-genome sequencing of all MPXV cases (80%:  $n=1$ ) **Methods:** Whole-genome sequencing of all MPXV cases (80%; n=178/219) analysed against <sup>35</sup>sequences from public databases (n=2695). Bayesian approaches were used to infer the 36 divergence time between sequences from different subclades and transmission events 37 involving different countries. <sup>38</sup>**Results:** The circulating virus belonged to the clade IIb B.1 lineage and, notably, the 39 presence of twelve separable and highly-supported subclades consistent with multiple<br>40 introductions into the country. Such a hypothesis of multiple importation events was introductions into the country. Such a hypothesis of multiple importation events was 41 supported further by the estimation of the time to the divergence of subclades. Additionally,<br>42 inferred MPXV transmissions involving different countries and continents were indicative of inferred MPXV transmissions involving different countries and continents were indicative of <sup>43</sup>an extended international spread. The analysis of the mutations in the Irish sequences <sup>44</sup>revealed 93% of the mutations were from cytosine to thymine (or from guanine to adenine), 15 leading to a high number of non-synonymous mutations across the subclades.<br>16 **Conclusion:** In the context of extremely high national sequencing coverage, v **Conclusion:** In the context of extremely high national sequencing coverage, we provide new 47 insights into the international origin and transmission dynamics supporting multiple<br>48 introductions into the Republic of Ireland introductions into the Republic of Ireland. 49 <sup>50</sup>**Keywords:** mpox virus, monkeypox virus, genome, epidemiological analysis, epidemic <sup>51</sup>dynamics. <sup>53</sup>**Conflict of Interests.**  54 None to declare.

It is made available under a CC-BY 4.0 International license.

## 56 **Introduction**<br>57 Mpox (Monke

Mpox (Monkeypox) virus (MPXV) is a double-stranded DNA virus in the genus <sup>58</sup>*Orthopoxvirus* within the *Poxviridae* family (Xiang and White, 2022) and is regarded as a <sup>59</sup>High consequence Infectious Agent (HCID). Despite its name, the natural reservoir of the 60 virus remains unknown but it is transmitted among small mammals, such as rodents (W.H.O., <sup>61</sup>2023). The length of the MPXV genome is approximately 197.2 kb encoding a predicted 191 62 proteins, and is genetically closely related to the variola (smallpox) virus. Mpox symptoms<br>63 can last between two and four weeks and include fever, sore throat, headache, muscle aches 63 can last between two and four weeks and include fever, sore throat, headache, muscle aches,<br>64 low energy, swollen lymph nodes and rash: however, the combination and severity of these low energy, swollen lymph nodes and rash; however, the combination and severity of these <sup>65</sup>symptoms varies among patients and some severe cases can develop skin lesions (Saxena et <sup>66</sup>al., 2023). The virus is transmitted to humans by direct contact with infected animals, through 67 scratches and bites, or materials, such as contaminated clothes or needles, or by contact with <sup>68</sup>lesions of infected people. Sexual transmission appears to be a major route of transmission, in 69 particular during the recent outbreak, (W.H.O., 2023; Sun et al., 2023).<br>70 Two maior clades of MPXV have been recognised as circulating Two major clades of MPXV have been recognised as circulating endemically in <sup>71</sup>Africa, one in Central Africa (clade I) and the other one in West Africa (clade II) with 72 differing transmissibility and case fatality rates (Quarleri et al., 2022). In this context, an 73 increased number of cases started appearing internationally in May 2022, and were <sup>74</sup>characterised as part of the West African clade II. Based on viral phylogenetic properties and 75 epidemiological evidence of increased human-to-human transmission outside of endemic<br>76 eeographic locations. MPXV cases in the context of the 2022 outbreak were classified wit geographic locations, MPXV cases in the context of the 2022 outbreak were classified within <sup>77</sup>a distinct subclade, termed IIb (Gigante et al., 2022). The outbreak has been reported across 78 multiple countries on different continents and has differed from earlier outbreaks of clade I<br>79 and IIa. in terms of host age (54.3% of individuals in their thirties), sex (predominantly mal and IIa, in terms of host age (54.3% of individuals in their thirties), sex (predominantly male), 80 and sexual transmission the most commonly reported (Bragazzi et al., 2023). 81 The overall case fatality rate of mpox has been estimated at 8.7%, though substantial 82 differences have been observed between clades: estimated as 10.6% for clade I, versus 1-<br>83 3.6% for clade IIa (Bunge et al., 2022; Americo et al., 2023), and a mortality rate in the ra <sup>83</sup>3.6% for clade IIa (Bunge et al., 2022; Americo et al., 2023), and a mortality rate in the range <sup>84</sup>0.01-1.81% for Clade IIb associated with the 2022 event (Reda et al., 2022). Whilst the 2022 85 international outbreaks of MPXV clade IIb had milder clinical severity, therefore, it 86 represented a significant public health concern due to the significant increase in reported 87 sexual transmission and concerns regarding "spill over" into other more susceptible 88 populations (Sun et al., 2023; Borges et al., 2023). Due to the unprecedented nature of the <sup>89</sup>mpox epidemic outbreaks outside endemic African countries and its classification as an

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- <sup>90</sup>HCID, the WHO declared a Public Health Emergency of International Concern (PHEIC) in
- 91 July 2022 (Wenham and Eccleston-Turner, 2022).
- 92 MPXV clade case designation by genomic analyses facilitates an evidence-based<br>93 assessment of transmissibility and the ability to distinguish new importation events. To
- assessment of transmissibility and the ability to distinguish new importation events. To
- <sup>94</sup>establish a comprehensive genomic epidemiological baseline for national surveillance in the
- 95 Republic of Ireland, whole-genome sequencing (WGS) was performed at the National Virus
- 
- 96 Reference Laboratory for all available MPXV laboratory-confirmed positive cases. Genome<br>97 sequences (n=178 sequences) were obtained covering an extremely high percentage (>80% c 97 sequences (n=178 sequences) were obtained covering an extremely high percentage ( $>80\%$  of cases) of all cases between May and November 2022 (n=219 cases). This comprehensive
- 98 cases) of all cases between May and November 2022 (n=219 cases). This comprehensive<br>99 MPXV genomic dataset was analysed further to elucidate the dynamics of the 2022 MPX
- 99 MPXV genomic dataset was analysed further to elucidate the dynamics of the 2022 MPXV<br>100 epidemic in the Republic of Ireland to ascertain whether single or multiple introductions of
- <sup>100</sup>epidemic in the Republic of Ireland to ascertain whether single or multiple introductions of
- 101 the virus were responsible.

It is made available under a CC-BY 4.0 International license.

## 102 **Materials & Methods**<br>103 **Sample collection.**

#### **Sample collection.**

- 104 Samples (predominantly swabs of skin lesions/pustules transported in virus transport media ,<br>105 VTM) were received from 219 symptomatic individuals who presented for medical attention
- <sup>105</sup>VTM)) were received from 219 symptomatic individuals who presented for medical attention.
- <sup>106</sup>Following lysis and inactivation in a Containment Level 3 (CL3) facility with a VTM to
- 107 guanidinium isothiocyanate lysis buffer mixed in a ratio of 1:2.5, total nucleic acids were
- 108 extracted on the Roche MagNA Pure 96 platform as follows:  $200 \mu$ L of swab material in
- 109 VTM was added to 500  $\mu$ L Roche lysis buffer, and, following external lysis, were extracted<br>110 on the Roche MagNA Pure 96 system (input volume 450  $\mu$ L and eluted in 100  $\mu$ L).
- 110 on the Roche MagNA Pure 96 system (input volume 450  $\mu$ L and eluted in 100  $\mu$ L).<br>111 Alternatively. DNA from 200  $\mu$ L of material in VTM was extracted using the Oiage
- 111 Alternatively, DNA from 200  $\mu$ L of material in VTM was extracted using the Qiagen<br>112 OIAamp DNA Mini kit. according to the manufacturer's instructions.
- QIAamp DNA Mini kit, according to the manufacturer's instructions.
- 113

### <sup>114</sup>**Molecular Diagnostics.**

- 115 Real-time PCR was performed on the ABI7500 SDS platform employing initially the pan-<br>116 *Orthopoxvirus* zoonotic (non-variola) RT-PCR kit (Altona); for logistical reasons the assay
- <sup>116</sup>*Orthopoxvirus* zoonotic (non-variola) RT-PCR kit (Altona); for logistical reasons the assay
- was switched to the MPXV generic assay described by Li et al. (Li et al., 2010). However, a<br>118 CDC notification of a rare but significant deletion in the target TNF gene motivated to
- <sup>118</sup>CDC notification of a rare but significant deletion in the target TNF gene motivated to
- 119 change the assay to the LDT pan-*Orthopoxvirus* assay currently in use (Schroeder and 120 Nitsche, 2010).
- Nitsche, 2010).
- 121

#### <sup>122</sup>**Whole-Genome Sequencing.**

- 123 MPXV qPCR positive samples were processed for WGS following a tiled amplicon approach<br>124 and next-generation sequencing (NGS) approach employing Oxford Nanopore Technologies
- 124 and next-generation sequencing (NGS) approach employing Oxford Nanopore Technologies<br>125 (ONT). Tiled amplicons were generated from each sample employing two separate MPXV
- <sup>125</sup>(ONT). Tiled amplicons were generated from each sample employing two separate MPXV
- 126 primer pools (P/N 50025, MBS), according to the manufacturer's instructions (Matthijs 127 Welkers et al., 2022). Amplicons were barcoded employing the Rapid Barcoding Kit 96
- Welkers et al., 2022). Amplicons were barcoded employing the Rapid Barcoding Kit 96
- 128 (SQK-RBK110.96; ONT) and loaded onto a R9.4.1 flow cell (FLO-MIN106D; ONT)<br>129 with 23 samples and a negative control on each run. The data generated were basecalled an
- with 23 samples and a negative control on each run. The data generated were basecalled and<br>130 demultiplexed with Guppy v5.1.13 (ONT). The sequence reads were trimmed to remove
- demultiplexed with Guppy v5.1.13 (ONT). The sequence reads were trimmed to remove
- 131 adapters and barcoded sequences with Porechop v.0.3.2pre
- <sup>132</sup>(https://github.com/rrwick/Porechop). NGS reads were assembled employing a MPXV
- <sup>133</sup>genome sampled in November of 2021 in the United States of America (GenBank
- <sup>134</sup>ON676708) as the reference. The assembled consensus genome sequences were deposited in
- <sup>135</sup>GenBank (https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers OR146268-

It is made available under a CC-BY 4.0 International license.

136 OR146445 and also in GISAID (Supplementary Table S2). MPXV clades were assigned 137 following the automatic assignment by GISAID after data submission. 138 All multiple sequence alignments (MSA) were performed with MAFFT by the<br>139 algorithm FFT-NS-1 (Katoh et al., 2019). Phylogenies were inferred using a maximum

139 algorithm FFT-NS-1 (Katoh et al., 2019). Phylogenies were inferred using a maximum-

140 likelihood (ML) approach with RAxML using the general time reversible (GTR) substitution

<sup>141</sup>model and support for the branches was estimated with a bootstrap approach considering 500

142 repetitions (Stamatakis, 2014). MSA included ON676708 as reference to annotate the coding<br>143 regions and to analyse the effects of the nucleotide mutations as amino acid substitutions in

143 regions and to analyse the effects of the nucleotide mutations as amino acid substitutions in<br>144 the encoded proteins with only mutations on nucleotides supported by sequence denth  $> 20$ 

144 the encoded proteins with only mutations on nucleotides supported by sequence depth  $>$  20<br>145 reads analysed further.

- reads analysed further.
- 146<br>1

#### <sup>147</sup>**Inferring time to the most recent common ancestor.**

<sup>148</sup>The divergence times of the different MPXV subclades to the most recent common ancestor

149 (tMRCA) were inferred using BEAST2 v2.5.7 (Bouckaert et al., 2019). The reference<br>150 ON676708 was employed as an outgroup for rooting the tree. The substitution model v

<sup>150</sup>ON676708 was employed as an outgroup for rooting the tree. The substitution model was

151 chosen using the model test in RAxML GUI (Edler et al., 2021) and the Bayesian information<br>152 criterion (BIC), choosing the Hasegawa-Kishino-Yano (HKY) substitution model as the best

<sup>152</sup>criterion (BIC), choosing the Hasegawa-Kishino-Yano (HKY) substitution model as the best

153 fit for the sequences requiring the least amount of parameters with a proportion of invariant<br>154 sites (+D. The different models with a constant clock or an uncorrelated Optimised Relaxed

<sup>154</sup>sites (+I). The different models with a constant clock or an uncorrelated Optimised Relaxed

<sup>155</sup>Clock (ORC) (Douglas et al., 2021), with the population modelled either as constant size,

156 exponential growth or Bayesian skyline, were considered and compared to identify the most

157 likely model among the six combinations. All models were calibrated with the collection date<br>158 of the samples Each model was executed for  $10^8$  steps sampling every  $10^4$  to assure an

- 158 of the samples. Each model was executed for  $10^8$  steps sampling every  $10^4$  to assure an
- <sup>159</sup>Effective Sample Size (ESS) > 100 for all parameters in the models, i.e. the number of
- 160 effectively independent draws for each parameter from the posterior distribution that the<br>161 Markov chain was equivalent to. The model parameters were summarised and explored v

Markov chain was equivalent to. The model parameters were summarised and explored with

162 Tracer 1.7.1, and tree of the best model was summarised using the 'treannotator' programme<br>163 in the BEAST bundle to extract the divergence time and the mutation rate of the subclades.

in the BEAST bundle to extract the divergence time and the mutation rate of the subclades.

#### <sup>165</sup>**Testing association with international MPXV genome sequences.**

166 Contemporaneous sequences were downloaded from the MPXV database in GISAID

<sup>167</sup>(https://gisaid.org/) with the filtering criteria requiring near complete genome sequences and

- <sup>168</sup>high quality (>90% genome coverage) (Supplementary Table S1). Additionally, reference
- 169 sequences from previous MPXV outbreaks were downloaded from GenBank (Supplementary

It is made available under a CC-BY 4.0 International license.



- Ethics Committee Sciences analysed data with the Research Ethics Reference Number: LS-
- 187 LRSD-23-197-Gonzalez-Hare.

It is made available under a CC-BY 4.0 International license.

#### <sup>188</sup>**Results**

189 **Characteristics of the 2022 MPXV outbreak.** The 219 laboratory-confirmed MPXV qPCR-

190 positive samples analysed in the present study were collected between May and November<br>191 2022. As reported by the Health Service Executive (HSE) of the Republic of Ireland (ROI).

- <sup>191</sup>2022. As reported by the Health Service Executive (HSE) of the Republic of Ireland (ROI),
- 192 the majority of cases were males with a median age of 35 years with 79.8% aged between 18-
- 193 44 years (HPSC, 2023). These cases were distributed over time with the peak in August ( $> 60$
- 194 cases) (Fig. 1).





195 196 **Figure 1. MPXV cases reported in the Republic of Ireland.** The horizontal and vertical axes represent the epidemiological week of 2022 when the samples were received and the 197 axes represent the epidemiological week of 2022 when the samples were received and the 198 total number of reported cases across the country, respectively. The distribution of subclad 198 total number of reported cases across the country, respectively. The distribution of subclades<br>199 assigned by GISAID has been coloured according to the legend. Months are shown on the top 199 assigned by GISAID has been coloured according to the legend. Months are shown on the top of the panel.  $200$  of the panel.<br>201

202 **WGS of Irish MPXV in 2022.** Among the 219 cases, 178 (80%) were successfully<br>203 sequenced, of which 175 met the >90% coverage threshold with an average genome sequenced, of which 175 met the  $\geq$ 90% coverage threshold with an average genome coverage 204 of 99.3  $\pm$  2% (Supplementary Table S2). The high coverage of the sequences facilitated the<br>205 mutational analysis compared to the MPXV clade IIb reference genome ON676708, which mutational analysis compared to the MPXV clade IIb reference genome ON676708, which 206 was chosen as reference. The transition/transversion ratio was 22.8, with 286 positions<br>207 showing mutations relative to the reference genome. Of the total number of mutations, showing mutations relative to the reference genome. Of the total number of mutations, 47% 208 and 46% were transitions C to T and G to A, respectively (Supplementary Table S3). Relative<br>209 to the reference genome annotation, these mutations were approximately seven times more to the reference genome annotation, these mutations were approximately seven times more 210 frequent in coding regions than in the non-coding regions (Supplementary Table S4). 211 Moreover, 154 mutations were non-synonymous mutations while 100 were synonymous 212 mutations with 32 characterised as non-coding mutations (Supplementary Table S4). These

It is made available under a CC-BY 4.0 International license.

- 213 mutations distributed into the different GISAID-assigned clades as follows: a total of 11<br>214 mutations were considered common to all sequenced samples with their presence in >90
- mutations were considered common to all sequenced samples with their presence in >90% of
- 
- 215 the sequenced samples; 194 mutations were identified as isolated single nucleotide variants<br>216 (SNV) present in only one sequence, among them,  $132$  (n=105) were in the IIb B.1 subclade (SNV) present in only one sequence, among them,  $132$  (n=105) were in the IIb B.1 subclade
- 217 (dark green sequences in Fig. 2). Conversely, a total of 104 SNVs were distributed and
- 218 characteristic to each subclade (Fig. 2), i.e. common to all the sequences under the same
- 219 subclade in the format IIb B.1.\* as follows B.1.1: 6 SNV (n=6), B.1.2: 20 (n=9), B.1.3: 10
- 220  $(n=11)$ , B.1.5: 7 (n=2), B.1.7: 27 (n=28), B.1.8: 8 (n=1), B.1.9: 5 (n=2), B.1.10: 13 (n=6),<br>221 B.1.11: 4 (n=1), B.1.12: 2 (n=3), and B.1.15: 2 (n=1). The remaining 28 mutations
- 221 B.1.11: 4 (n=1), B.1.12: 2 (n=3), and B.1.15: 2 (n=1). The remaining 28 mutations<br>222 corresponded to variants within each subclade. These SNV have accumulated follo
- 222 corresponded to variants within each subclade. These SNV have accumulated following<br>223 divergence among subclades and point mutations were still accumulating, as was most
- divergence among subclades and point mutations were still accumulating, as was most
- 224 evident in the basal subclade IIb B.1.



It is made available under a CC-BY 4.0 International license.

<sup>226</sup>**Figure 2. The MPXV phylogenetic tree for whole-genome sequences of Irish cases and reference genomes.** The tree was rooted with an MPXV Clade I sequence (GISAID acc.<br>228 number: EPI ISL 13058460) and other reference sequences were added to corroborate the 228 number: EPI\_ISL\_13058460) and other reference sequences were added to corroborate the<br>229 clade assignments for the sequences. All external sequences show the corresponding 229 clade assignments for the sequences. All external sequences show the corresponding<br>230 accession number and short description of their origin. Support for branching nodes. 230 accession number and short description of their origin. Support for branching nodes,<br>231 estimated with a bootstrap approach (500 repetitions), is shown for support >70%. Ti 231 estimated with a bootstrap approach (500 repetitions), is shown for support  $\geq$ 70%. Tip names<br>232 have been coloured according to the subclade as shown on the colour legend. The scale of the 232 have been coloured according to the subclade as shown on the colour legend. The scale of the 233 tree represents  $5\times10^{-4}$  mutations per nucleotide site. tree represents  $5\times10^{-4}$  mutations per nucleotide site.<br>234 <sup>235</sup>The subclades assigned by GISAID, the number of characteristic mutations per

236 subclade, and the phylogenetic relationships among our samples and sequences from previous<br>237 outbreaks confirmed the identity of the cases as belonging to the MPXV clade IIb B.1 (Fig. 2). outbreaks confirmed the identity of the cases as belonging to the MPXV clade IIb B.1 (Fig. 2). <sup>238</sup>Furthermore, at least twelve phylogenetically separable and highly-supported subclades were 239 suggested to circulate simultaneously in ROI during the 2022 epidemic (Fig. 2). The cases 240 identified during the outbreak belonged to the subclade IIb B.1, however, during the 20 241 weeks period when these cases were detected, distinct variants were identified suggesting at 242 least two alternative hypotheses to explain these findings: (i) the twelve subclades were<br>243 introduced to ROI in a single initial wave that evolved locally, or (ii) a flow of new subc <sup>243</sup>introduced to ROI in a single initial wave that evolved locally, or (ii) a flow of new subclades

- 244 to the country in multiple separate importation events.
- 

<sup>246</sup>**Dating the divergence of the Irish MPXV subclades.** To investigate further the possible 247 origins of the multiple subclades circulating in ROI, the divergence times of the different<br>248 subclades were inferred emploving a Bavesian approach. The comparison of the considere subclades were inferred employing a Bayesian approach. The comparison of the considered 249 Bayesian models demonstrated that a combination of a Bayesian skyline modelling of the<br>250 population growth with an uncorrelated relaxed clock was the model with the highest <sup>250</sup>population growth with an uncorrelated relaxed clock was the model with the highest 251 likelihood for the observed genomic data (Table 1). The dating of the tMRCA of the different<br>252 subclades to mid-May (2022.37, 95% HPD [2022.28, 2022.40], corresponding to <sup>252</sup>subclades to mid-May (2022.37, 95% HPD [2022.28, 2022.40], corresponding to <sup>253</sup>epidemiological weeks 15 and 21 of 2022, respectively) was consistent with divergence prior 254 to the outbreaks in the ROI (Table 1, Fig. 3). This also provided evidence in support of the 255 hypothesis that multiple introductions, not a single importation event, of new and diverse<br>256 variants into Ireland occurred throughout the 2022 outbreak event. Furthermore, while other <sup>256</sup>variants into Ireland occurred throughout the 2022 outbreak event. Furthermore, while other 257 phylogenetic groups were observed to have diverged as early as the last week of May, at least 258 two clades, namely IIb B.1.9 and B.1.12, diverged in August 2022 and, given that no earlier 259 cases assigned to these clades were detected, it is considered more likely they were 260 introduced into the country later in the course of the outbreak. Additionally, other sub-<br>261 clusters in IIb B.1 and B.1.2 are suggested to have diverged after August and as late as clusters in IIb B.1 and B.1.2 are suggested to have diverged after August and as late as

It is made available under a CC-BY 4.0 International license.

- 262 September 2022 (Fig. 3). It is noteworthy that despite the best fit being a Bayesian skyline<br>263 with the ORC, all the inferred models had very similar dates for the tMRCA and relatively
- with the ORC, all the inferred models had very similar dates for the tMRCA and relatively
- high mutation rates in the range [7.2E-5, 1.3E-4] which is notably higher than the  $10^{-6}$  mutation rate previously reported for the family *Orthopoxviruses* (Babkin et al., 2022).
- <sup>265</sup>mutation rate previously reported for the family *Orthopoxviruses* (Babkin et al., 2022).

![](_page_10_Figure_6.jpeg)

266<br>267 **Figure 3. Bayesian inferred phylogenetic tree with the most likely time of the MRCA for the different clades in the Republic of Ireland.** The circular tree represents the 175 ROI

268 **the different clades in the Republic of Ireland.** The circular tree represents the 175 ROI sequences rooted with ON676708 (IIb A.1). The nodes show the most likely day of the year.

269 sequences rooted with ON676708 (IIb A.1). The nodes show the most likely day of the year 270 2022 for the MRCA, the scale for these days and the corresponding months are shown as blue

270 2022 for the MRCA, the scale for these days and the corresponding months are shown as blue<br>271 concentric circles. Clades are coloured as in Fig. 2 and have been added to the tip names for 271 concentric circles. Clades are coloured as in Fig. 2 and have been added to the tip names for reference.

- 272 reference.<br>273
- 

![](_page_11_Picture_504.jpeg)

### <sup>274</sup>**Table 1. Comparison of Bayesian models and the inferred time to the MRCA of the MPXV clades in the Republic of Ireland.**

275

276

277

medRxiv preprint doi: https://doi.org/10.1101/2023.09.18.23295695; this version posted September 18, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grant is the presult of the authory funder medical state and the actual the actual the authority. Also have the preprint in perior of certified by peer reprint in perpetuity. In perform in perpetular,  $\alpha$ The copyright holder for this this version posted September 18, 2023. [;](https://doi.org/10.1101/2023.09.18.23295695) https://doi.1011101/01210111012020. Ite doi: medRxiv preprint in the dock of this set we september 18, 2023. It be docking to this in the docking to t

. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

It is made available under a CC-BY 4.0 International license

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

<sup>278</sup>**Uncovering possible origins of the MPXV introductions to Ireland.** As mentioned above, 279 the clade IIb subclade B.1 was predominant during the 2022 MPXV outbreak in ROI (n=105), 280 and consistent with the distribution in other locations for the same time period with between<br>281 33% and 74% of sequences from this subclade (Table 2). As some of the other circulating <sup>281</sup>33% and 74% of sequences from this subclade (Table 2). As some of the other circulating 282 subclades were suggested to have diverged some time prior to the first MPXV case detected 283 in the ROI (31 May 2022), the subclade sequences were compared with sequences from other 284 geographical locations to identify putative origins for the different clades and to explore<br>285 further the evidence for any transmission events within these individuals (Fig. 4. 285 further the evidence for any transmission events within these individuals (Fig. 4, 286 Supplementary Fig. S1 and Supplementary Fig. S2). Despite the conservative approximate Supplementary Fig. S1 and Supplementary Fig. S2). Despite the conservative approach used 287 to infer the transmission, requiring less than two generations and a support of  $>$  30% in the 288 Outbreaker2 inference, many nodes were connected across the different countries and Outbreaker2 inference, many nodes were connected across the different countries and 289 continents, reflecting the international transmission dynamics. Many of the inferred infectious<br>290 links supported the transmission between cases from the same geographical location as links supported the transmission between cases from the same geographical location as 291 community transmission in IIb B.1.9 and B.1.10 (Supplementary Fig. S2C-D) or the more<br>292 numerous cases in IIb B.1.1, B.1.2 and B.1.7 (Supplementary Fig. S1A, B. D). The Bavesi numerous cases in IIb B.1.1, B.1.2 and B.1.7 (Supplementary Fig.  $S1A$ , B, D). The Bayesian 293 analysis inferred strong support for importation events based on the collection dates and<br>294 bhylogenetic relationships among the sequences. The inference suggested importations is <sup>294</sup>phylogenetic relationships among the sequences. The inference suggested importations into <sup>295</sup>ROI from both Europe (United Kingdom, Portugal, Germany, Switzerland) and North and 296 South America (the United States of America, Colombia, and Brazil) (Fig. 4).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

![](_page_13_Figure_2.jpeg)

297<br>298

<sup>298</sup>**Figure 4. Summary of inferred transmissions among countries detected in the subclades**  299 **detected in the Republic of Ireland.** The nodes represent countries where the lineages of subclades in the clade IIb B.1 were sequenced. The size of the nodes reflects the number of 300 subclades in the clade IIb B.1 were sequenced. The size of the nodes reflects the number of sequences reported by each country. The arrows represent the direction of inferred 301 sequences reported by each country. The arrows represent the direction of inferred<br>302 transmission events. transmission events.

303

<sup>304</sup>**Table 2. MPXV clade IIb subclades in GISAID from the 2022 outbreak.** 

| <b>Subclades</b>  | Location       |               |                      |                      |      |                |              |
|-------------------|----------------|---------------|----------------------|----------------------|------|----------------|--------------|
|                   | <b>Ireland</b> | <b>Europe</b> | <b>North America</b> | <b>South America</b> | Asia | <b>Oceania</b> | <b>Cases</b> |
| $I$ Ib B.1        | 60%            | 74%           | 60%                  | 61%                  | 33%  | 100%           | 1874         |
| <b>IIb B.1.1</b>  | 3%             | 7%            | 4%                   | 22%                  | 11%  |                | 217          |
| <b>IIb B.1.2</b>  | 5%             | 3%            | 12%                  | 2%                   | 22%  |                | 195          |
| <b>IIb B.1.3</b>  | 6%             | 3%            | 4%                   |                      | 26%  |                | 102          |
| <b>IIb B.1.5</b>  | 1%             | 3%            | 1%                   |                      | 4%   |                | 56           |
| <b>IIb B.1.7</b>  | 16%            | 4%            | 5%                   | 1%                   | 4%   |                | 137          |
| <b>IIb B.1.8</b>  | 1%             | 2%            | 3%                   |                      |      |                | 51           |
| <b>IIb B.1.9</b>  | 1%             | 1%            | 0%                   | 4%                   |      |                | 31           |
| <b>IIb B.1.10</b> | 3%             | 1%            | 0%                   | 8%                   |      |                | 50           |
| <b>IIb B.1.11</b> | 1%             | 0%            | 5%                   | 1%                   |      |                | 65           |
| <b>IIb B.1.12</b> | 2%             | 1%            | 4%                   | 1%                   |      |                | 50           |
| <b>IIb B.1.15</b> | 1%             | 1%            | 0%                   | 1%                   |      |                | 14           |
| <b>Cases</b>      | 175            | 1253          | 1074                 | 312                  | 27   | 1              |              |

It is made available under a CC-BY 4.0 International license.

<sup>306</sup>**Discussion** The first detections of MPXV in Ireland was notified on May  $31<sup>st</sup>$  2022 with the earliest onset of symptoms on May  $13<sup>th</sup>$ . The major peak of cases was in and August 2022 and declined<br>309. Significantly since this time. A similar observation has been shared in other iurisdictions significantly since this time. A similar observation has been shared in other jurisdictions <sup>310</sup>where the numbers of cases have decreased significantly worldwide. The explanation for the 311 decline in case numbers is likely multifactorial including effective public health 312 communication regarding protective measures, the subsequent introduction of safe practices<br>313 to mitigate against transmission in vulnerable groups. Parallel with this the introduction of 313 to mitigate against transmission in vulnerable groups. Parallel with this the introduction of<br>314 targeted vaccination policy to protect those at most risk and the reduced mass gathering 314 targeted vaccination policy to protect those at most risk and the reduced mass gathering<br>315 events in late 2022 (HSE, 2022: Yang et al., 2023). The smallpox vaccine was offered as 315 events in late 2022 (HSE, 2022; Yang et al., 2023). The smallpox vaccine was offered as<br>316 MPXV prophylaxis and it has been suggested that the previous cessation of the smallpox <sup>316</sup>MPXV prophylaxis and it has been suggested that the previous cessation of the smallpox 317 vaccination around the world could have been one of the factors contributing to the<br>318 emergence of the current outbreak (Bunge et al., 2022). emergence of the current outbreak (Bunge et al., 2022). 319 Since the 2022 outbreak in the ROI described here, there have been further sporadic<br>320 cases (n=5) notified in December 2022, January 2023 and August 2023, and internationally cases ( $n=5$ ) notified in December 2022, January 2023 and August 2023, and internationally a 321 surge of cases in East Asia during July and August (Murphy, 2023). This indicates<br>322 importation events are likely occurring with the potential for onward transmission. importation events are likely occurring with the potential for onward transmission. Such 323 cases highlight the need for vigilance, early detection with timely genomic surveillance and<br>324 rapid public sharing of sequences to monitor for potential amino acid substitutions and for rapid public sharing of sequences to monitor for potential amino acid substitutions and for 325 MPXV clade changes over time on both national and international levels. The availability of<br>326 the large genomic epidemiological baseline from 2022 described in this study will facilitate the large genomic epidemiological baseline from 2022 described in this study will facilitate 327 the delineation of transmission patterns and, specifically, the ability to distinguish imported<br>328 from autochthonous transmission events as the priority must be to mitigate against further 328 from autochthonous transmission events as the priority must be to mitigate against further<br>329 disease transmission by preventing the establishment of recalcitrant reservoirs arising from disease transmission by preventing the establishment of recalcitrant reservoirs arising from 330 potential silent transmission, i.e. in asymptomatic cases (Mizushima et al., 2023), in different<br>331 eeographical regions which will seed further outbreaks. geographical regions which will seed further outbreaks.

332 Our results of MPXV genomic epidemiological analysis demonstrates multiple<br>333 introductions of the virus to the ROI with evidence for continued divergence during 20 <sup>333</sup>introductions of the virus to the ROI with evidence for continued divergence during 2022. Such results were consistent with the national published reports documenting that 50.9%<br>335 (n=116/190) of cases were associated with a recent history of international travel in the 2  $(n=116/190)$  of cases were associated with a recent history of international travel in the 21 336 days prior to symptom onset (HPSC, 2023). Our analyses also contextualised the Irish cases <sup>337</sup>into the global genomic epidemiology of the unprecedented international MPXV 2022 338 outbreak (Isidro et al., 2022), with the presence of subclades with higher prevalence in 339 different continents suggested to be transmitted to cases in Ireland.

It is made available under a CC-BY 4.0 International license.

340 The dominant clade of circulating MPXV in Ireland was suggested to accumulate <sup>341</sup>mutations at a rate that was at least an order of magnitude higher than previously reported 342 (Babkin et al., 2022), which is in keeping with recent data from a number of other studies<br>343 (Yadav et al., 2022: Luna et al., 2022). The Bavesian-inferred population model suggested <sup>343</sup>(Yadav et al., 2022; Luna et al., 2022). The Bayesian-inferred population model suggested an <sup>344</sup>increase in the effective population size early on in the outbreak that gave origin to many of 345 the different subclades, as a probable consequence of the extensive human-to-human 346 transmission events and adaptation and modification by the human host immune response<br>347 (Yang et al., 2023). Such results could explain the distinctive pattern of the increases in the 347 (Yang et al., 2023). Such results could explain the distinctive pattern of the increases in the<br>348 mumber of accumulated mutations as the virus was replicating and being transmitted. The 348 number of accumulated mutations as the virus was replicating and being transmitted. The<br>349 analysis of mutational patterns amongst our MPXV cases strongly supported the hypothes 349 analysis of mutational patterns amongst our MPXV cases strongly supported the hypothesis<br>350 that much of this divergence is driven by the effects of enzymes of the APOBEC cytosine that much of this divergence is driven by the effects of enzymes of the APOBEC cytosine 351 deaminase family where C to T (or G to A on the lagging strand) mutations predominated<br>352 (Isidro et al., 2022), as was also observed in the evolution of SARS-CoV-2 during the <sup>352</sup>(Isidro et al., 2022), as was also observed in the evolution of SARS-CoV-2 during the 353 COVID-19 pandemic (Mourier et al., 2021). Therefore, while MPXV may still be considered<br>354 a zoonotic infection (W.H.O., 2023), viral phylogenetic and Bavesian analysis of local and a zoonotic infection (W.H.O., 2023), viral phylogenetic and Bayesian analysis of local and 355 international transmission dynamics provide evidence in support of sustained adaptation of<br>356 the virus to the human and a potential risk to public health by altered transmission (Yang et <sup>356</sup>the virus to the human and a potential risk to public health by altered transmission (Yang et 357 al., 2023; Luna et al., 2022)<br>358 The extremely high s

The extremely high sequencing coverage in our study facilitated robust phylogenetic 359 inferences to be drawn by reducing uncertainty as to the direction and dating of the<br>360 transmission between cases. With lower national genomic surveillance, uncertainty transmission between cases. With lower national genomic surveillance, uncertainty increases 361 and the number of possible transmission routes and epidemiological variables also grows<br>362 exponentially As a consequence this limits the amount of information that can be drawn 362 exponentially. As a consequence, this limits the amount of information that can be drawn<br>363 from the gathered data. The combination of epidemiological data with high sequencing from the gathered data. The combination of epidemiological data with high sequencing 364 coverage for a particular outbreak can lead to insights into the origins, the transmission <sup>365</sup>dynamics and even susceptibility of different populations as was implemented during the 366 COVID-19 pandemic in tracing the epidemiological dynamics of SARS-CoV-2 (Lucey et al., 367 2021: Hare et al., 2021). 2021; Hare et al., 2021).

368 In conclusion, through detailed phylogenetic analysis of MPXV cases, in the context<br>369 of extremely high sequencing coverage by international comparison performed in the Irish <sup>369</sup>of extremely high sequencing coverage by international comparison performed in the Irish 370 population, we provide evidence for multiple introductions during the 2022 outbreak<br>371 underscoring the possibility that importation events could recur here and elsewhere po <sup>371</sup>underscoring the possibility that importation events could recur here and elsewhere posing a 372 continued threat to public health. This dataset provides an epidemiological baseline to 373 monitor future MPXV importation events by analogy to that employed for other pathogen

It is made available under a CC-BY 4.0 International license.

<sup>374</sup>genomics efforts including influenza, measles and polio. The surveillance of MPXV genetic

<sup>375</sup>diversity also enables the assessment of the effectiveness of interventions to contain epidemic

- 376 threats and the rational development of target-specific prophylactic vaccines. Furthermore,<br>377 with a better understanding of the nature of MPXV introductions into Ireland, and their
- with a better understanding of the nature of MPXV introductions into Ireland, and their
- 378 subsequent transmission dynamics, evidence based public health interventions can be planned
- 379 and implemented, and mathematical modelling of mpox epidemiology can inform
- 380 vaccination policy.
- 

### <sup>382</sup>**Acknowledgements**

383 We gratefully acknowledge all authors from reference laboratories who submitted genome<br>384 sequences to public databases. This study was partially supported by AMED under the gran

sequences to public databases. This study was partially supported by AMED under the grant

385 number JP223fa627005.

## <sup>387</sup>**Contributions**

<sup>388</sup>**Gabriel Gonzalez**: data analysis and draft manuscript preparation; **Michael Carr**: genome 389 sequencing and manuscript edition; **Tomás M. Kelleher**: genome sequencing; **Emer O'Byrne**: sample extraction, genome sequencing and manuscript edition; **Weronika Banka**: <sup>390</sup>**O'Byrne**: sample extraction, genome sequencing and manuscript edition; **Weronika Banka**: <sup>391</sup>sample extraction, genome sequencing and manuscript edition; **Brian Keogan**: sample <sup>392</sup>location and extraction, manuscript edition; **Charlene Bennett**: protocols validation; <sup>393</sup>**Geraldine Franzoni**: protocols validation; **Patrice Keane**: genome sequencing and <sup>394</sup>manuscript edition; **Luke W. Meredith**: genome sequencing protocol; **Nicola Fletcher**: 395 genome sequencing and manuscript edition; **Jose Maria Urtasun-Elizari**: sequence analysis<br>396 and manuscript preparation: **Jonathan Dean**: data collection and analysis manuscript 396 and manuscript preparation; **Jonathan Dean**: data collection and analysis, manuscript edition: **Brendan Crowley**: sample collection, results validation and manuscript edition: edition; **Brendan Crowley**: sample collection, results validation and manuscript edition; <sup>398</sup>**Derval Igoe**: data evaluation and manuscript edition; **Eve Robinson**: data evaluation and <sup>399</sup>manuscript edition; **Greg Martin**: data evaluation and manuscript edition; **Jeff Connell**: 400 protocols validation; **Daniel Hare**: study oversight, manuscript preparation; Cillian F. De<br>401 Gascun: study oversight, manuscript preparation. All authors reviewed the results and **Gascun**: study oversight, manuscript preparation. All authors reviewed the results and 402 approved the final version of the manuscript.

It is made available under a CC-BY 4.0 International license.

#### <sup>405</sup>**References**

- 406 Xiang, Y.; White, A. Monkeypox virus emerges from the shadow of its more infamous<br>407 cousin: family biology matters. Emerg Microbes Infect. 2022 Dec:11(1):1768-1777.
- 407 cousin: family biology matters. Emerg Microbes Infect. 2022 Dec;11(1):1768-1777.<br>408 W.H.O. Mpox (monkeypox) Fact sheet: [modified 18-04-2023: cited 2023 28-07-2
- 408 W.H.O. Mpox (monkeypox) Fact sheet; [modified 18-04-2023; cited 2023 28-07-2023].<br>409 Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox
- 409 Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox<br>410 Saxena, S.K.; Ansari, S.; Maurya, V.K.; Kumar, S.; Jain, A.: Paweska, J.T.; Tri
- 410 Saxena, S.K.; Ansari, S.; Maurya, V.K.; Kumar, S.; Jain, A.; Paweska, J.T.; Tripathi, A.K.; 411 Abdel-Moneim. A.S. Re-emerging human monkevpox: A maior public-health debacle. J M
- 411 Abdel-Moneim, A.S. Re-emerging human monkeypox: A major public-health debacle. J Med<br>412 Virol. 2023 Jan:95(1):e27902.
- 412 Virol. 2023 Jan;95(1):e27902.<br>413 Sun. Y.O.: Chen. J.J.: Liu. M.C
- 413 Sun, Y.Q.; Chen, J.J.; Liu, M.C.; Zhang, Y.Y.; Wang, T.; Che, T.L.; Li, T.T.; Liu, Y.N.;<br>414 Teng, A.Y.; Wu, B.Z.; Hong, X.G.; Xu, O.; Lv, C.L.; Jiang, B.G.; Liu, W.; Fang, L.O.
- 414 Teng, A.Y.; Wu, B.Z.; Hong, X.G.; Xu, Q.; Lv, C.L.; Jiang, B.G.; Liu, W.; Fang, L.Q.<br>415 Mapping global zoonotic niche and interregional transmission risk of monkevpox: a
- 415 Mapping global zoonotic niche and interregional transmission risk of monkeypox: a<br>416 retrospective observational study. Global Health. 2023 Aug 17:19(1):58.
- 416 retrospective observational study. Global Health. 2023 Aug 17;19(1):58.<br>417 Ouarleri, J.; Delpino, M.V.; Galvan, V. Monkeypox: considerations for tl
- 417 Quarleri, J.; Delpino, M.V.; Galvan, V. Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. Geroscience. 2022
- 418 containment of the current outbreak in non-endemic countries. Geroscience. 2022<br>419 Aug:44(4):2095-2103.
- 419 Aug;44(4):2095-2103.<br>420 Gigante, C.M.: Korber
- 420 Gigante, C.M.; Korber, B.; Seabolt, M.H.; Wilkins, K.; Davidson, W.; Rao, A.K.; Zhao, H.; 421 Smith, T.G.: Hughes, C.M.; Minhai, F.; Waltenburg, M.A.; Theiler, J.; Smole, S.; Gallagher.
- 421 Smith, T.G.; Hughes, C.M.; Minhaj, F.; Waltenburg, M.A.; Theiler, J.; Smole, S.; Gallagher, 422 GR · Blythe D · Myers, R · Schulte, J · Stringer, J · Lee, P · Mendoza, R M · Griffin-Thoma
- 422 G.R.; Blythe, D.; Myers, R.; Schulte, J.; Stringer, J.; Lee, P.; Mendoza, R.M.; Griffin-Thomas, 423 L.A.: Crain, J.: Murray, J.: Atkinson, A.: Gonzalez, A.H.: Nash, J.: Batra, D.: Damon, I.:
- 423 L.A.; Crain, J.; Murray, J.; Atkinson, A.; Gonzalez, A.H.; Nash, J.; Batra, D.; Damon, I.; 424 McQuiston, J.: Hutson, C.L.; McCollum, A.M.; Li, Y. Multiple lineages of monkeypox v
- 424 McQuiston, J.; Hutson, C.L.; McCollum, A.M.; Li, Y. Multiple lineages of monkeypox virus<br>425 detected in the United States. 2021-2022. Science. 2022 Nov 4:378(6619):560-565.
- 425 detected in the United States, 2021-2022. Science. 2022 Nov 4;378(6619):560-565.<br>426 Bragazzi, N.L.: Kong, J.D.: Mahroum, N.: Tsigalou, C.: Khamisy-Farah, R.: Conver
- 426 Bragazzi, N.L.; Kong, J.D.; Mahroum, N.; Tsigalou, C.; Khamisy-Farah, R.; Converti, M.; 427 Wu, J. Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A
- 427 Wu, J. Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A<br>428 preliminary pooled data analysis and literature review. J Med Virol. 2023 Jan:95(1):e27931.
- 428 preliminary pooled data analysis and literature review. J Med Virol. 2023 Jan;95(1):e27931.<br>429 Bunge, E.M.: Hoet. B.: Chen. L.: Lienert. F.: Weidenthaler. H.: Baer. L.R.: Steffen. R. The
- 
- 429 Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The<br>430 changing epidemiology of human monkeypox-A potential threat? A systematic review. PLc 430 changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS<br>431 Negl Trop Dis. 2022 Feb:16(2):e0010141.
- 431 Negl Trop Dis. 2022 Feb;16(2):e0010141.<br>432 Americo, J.L.: Earl. P.L.: Moss. B. Viruler
- 432 Americo, J.L.; Earl, P.L.; Moss, B. Virulence differences of mpox (monkeypox) virus clades<br>433 I. IIa. and IIb.1 in a small animal model. Proc Natl Acad Sci U S A. 2023 Feb
- 433 I, IIa, and IIb.1 in a small animal model. Proc Natl Acad Sci U S A. 2023 Feb  $434$   $21:120(8):e2220415120$ .
- 434 21;120(8):e2220415120.<br>435 Reda. A.: Hemmeda. L.:
- 435 Reda, A.; Hemmeda, L.; Brakat, A.M.; Sah, R.; El-Qushayri, A.E. The clinical manifestations<br>436 and severity of the 2022 monkeypox outbreak among 4080 patients. Travel Med Infect Dis.
- and severity of the 2022 monkeypox outbreak among 4080 patients. Travel Med Infect Dis.<br>437 2022 Nov-Dec:50:102456.
- 437 2022 Nov-Dec;50:102456.<br>438 Borges, V.: Duque, M.P.: N
- 438 Borges, V.; Duque, M.P.; Martins, J.V.; Vasconcelos, P.; Ferreira, R.; Sobral, D.; Pelerito, 439 A.: de Carvalho. I.L.: Nuncio. M.S.: Borrego. M.J.: Roemer. C.: Neher. R.A.: O'Driscoll. N
- 439 A.; de Carvalho, I.L.; Nuncio, M.S.; Borrego, M.J.; Roemer, C.; Neher, R.A.; O'Driscoll, M.; 440 Rocha, R.: Lopo, S.: Neves, R.: Palminha, P.: Coelho, L.: Nunes, A.: Isidro, J.: Pinto, M.:
- 440 Rocha, R.; Lopo, S.; Neves, R.; Palminha, P.; Coelho, L.; Nunes, A.; Isidro, J.; Pinto, M.; 441 Santos, J.D.: Mixao, V.: Santos, D.: Duarte, S.: Vieira, L.: Martins, F.: Machado, J.:
- 
- 441 Santos, J.D.; Mixao, V.; Santos, D.; Duarte, S.; Vieira, L.; Martins, F.; Machado, J.;<br>442 Verissimo, V.C.; Grau, B.; Peralta-Santos, A.; Neves, J.; Caldeira, M.; Pestana, M.;
- 442 Verissimo, V.C.; Grau, B.; Peralta-Santos, A.; Neves, J.; Caldeira, M.; Pestana, M.; 443 Fernandes, C.: Caria, J.: Pinto, R.: Povoas, D.: Maltez, F.: Sa, A.I.: Salvador, M.B.:
- 443 Fernandes, C.; Caria, J.; Pinto, R.; Povoas, D.; Maltez, F.; Sa, A.I.; Salvador, M.B.; Teofilo, 444 E.; Rocha, M.; Moneti, V.; Duque, L.M.; FF, E.S.; Baptista, T.; Vasconcelos, J.; Casanova,
- 444 E.; Rocha, M.; Moneti, V.; Duque, L.M.; FF, E.S.; Baptista, T.; Vasconcelos, J.; Casanova, 445 S.: Mansinho, K.: Alves, J.V.: Alves, J.: Silva, A.: Alpalhao, M.: Brazao, C.: Sousa, D.: 445 S.; Mansinho, K.; Alves, J.V.; Alves, J.; Silva, A.; Alpalhao, M.; Brazao, C.; Sousa, D.; 446 Filipe, P.: Pacheco, P.: Peruzzu, F.: de Jesus, R.P.; Ferreira, L.: Mendez, J.: Jordao, S.: I
- 446 Filipe, P.; Pacheco, P.; Peruzzu, F.; de Jesus, R.P.; Ferreira, L.; Mendez, J.; Jordao, S.; Duarte, 447 F.: Goncalves, M.J.: Pena, E.: Silva, C.N.: Guimaraes, A.R.: Tavares, M.: Freitas, G.:
- 
- 447 F.; Goncalves, M.J.; Pena, E.; Silva, C.N.; Guimaraes, A.R.; Tavares, M.; Freitas, G.; 448 Cordeiro, R.: Gomes, J.P. Viral genetic clustering and transmission dynamics of the 2 448 Cordeiro, R.; Gomes, J.P. Viral genetic clustering and transmission dynamics of the 2022<br>449 mpox outbreak in Portugal. Nat Med. 2023 Sep 11.
- 449 mpox outbreak in Portugal. Nat Med. 2023 Sep 11.<br>450 Wenham. C.: Eccleston-Turner. M. Monkeypox as
- 450 Wenham, C.; Eccleston-Turner, M. Monkeypox as a PHEIC: implications for global health<br>451 governance. Lancet. 2022 Dec 17:400(10369):2169-2171. 451 governance. Lancet. 2022 Dec 17;400(10369):2169-2171.<br>452 Li. Y.: Zhao. H.: Wilkins. K.: Hughes. C.: Damon. I.K. Re
- 452 Li, Y.; Zhao, H.; Wilkins, K.; Hughes, C.; Damon, I.K. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods.
- 453 detection of monkeypox virus West African and Congo Basin strain DNA. J Virol Methods.<br>454 2010 Oct:169(1):223-227.
- 2010 Oct;169(1):223-227.

- 455 Schroeder, K.; Nitsche, A. Multicolour, multiplex real-time PCR assay for the detection of human-pathogenic poxyiruses. Mol Cell Probes. 2010 Apr:24(2):110-113.
- 456 human-pathogenic poxviruses. Mol Cell Probes. 2010 Apr;24(2):110-113.<br>457 Matthiis Welkers: M. Jonges: Ouden. A.v.d. onkeypox virus whole genom
- 457 Matthijs Welkers; M. Jonges; Ouden, A.v.d. onkeypox virus whole genome sequencing using<br>458 combination of NextGenPCR and Oxford Nanopore V.1: [cited 2023]. Available from:
- 458 combination of NextGenPCR and Oxford Nanopore V.1; [cited 2023]. Available from:<br>459 https://www.protocols.io/private/974ACB78F83911EC998C0A58A9FEAC02
- 459 https://www.protocols.io/private/974ACB78F83911EC998C0A58A9FEAC02<br>460 Katoh, K.: Rozewicki, J.: Yamada, K.D. MAFFT online service: multiple sequ
- 460 Katoh, K.; Rozewicki, J.; Yamada, K.D. MAFFT online service: multiple sequence alignment, 461 interactive sequence choice and visualization. Brief Bioinform. 2019 Jul 19:20(4):1160-1166.
- 161 interactive sequence choice and visualization. Brief Bioinform. 2019 Jul 19;20(4):1160-1166.<br>162 Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
- 462 Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large<br>463 phylogenies. Bioinformatics. 2014 May 1:30(9):1312-1313.
- 463 phylogenies. Bioinformatics. 2014 May 1;30(9):1312-1313.<br>464 Bouckaert. R.: Vaughan. T.G.: Barido-Sottani. J.: Duchene.
- 464 Bouckaert, R.; Vaughan, T.G.; Barido-Sottani, J.; Duchene, S.; Fourment, M.; Gavryushkina, 465 A.: Heled, J.: Jones, G.: Kuhnert, D.: De Maio, N.: Matschiner, M.: Mendes, F.K.: Muller,
- 465 A.; Heled, J.; Jones, G.; Kuhnert, D.; De Maio, N.; Matschiner, M.; Mendes, F.K.; Muller, 466 N.F.; Ogilvie, H.A.; du Plessis, L.; Popinga, A.; Rambaut, A.; Rasmussen, D.; Siveroni, I.;
- 466 N.F.; Ogilvie, H.A.; du Plessis, L.; Popinga, A.; Rambaut, A.; Rasmussen, D.; Siveroni, I.; 467 Suchard, M.A.; Wu. C.H.; Xie, D.; Zhang, C.; Stadler, T.; Drummond, A.J. BEAST 2.5; Articleri, A.J. B.
- 467 Suchard, M.A.; Wu, C.H.; Xie, D.; Zhang, C.; Stadler, T.; Drummond, A.J. BEAST 2.5: An<br>468 advanced software platform for Bayesian evolutionary analysis. PLoS Comput Biol. 2019
- 468 advanced software platform for Bayesian evolutionary analysis. PLoS Comput Biol. 2019<br>469 Apr:15(4):e1006650. 469 Apr;15(4):e1006650.<br>470 Edler. D.: Klein. J.: A
- 470 Edler, D.; Klein, J.; Antonelli, A.; Silvestro, D. raxmlGUI 2.0: A graphical interface and toolkit for phylogenetic analyses using RAxML. Methods in Ecology and Evolution.
- 471 toolkit for phylogenetic analyses using RAxML. Methods in Ecology and Evolution.<br>472  $2021:12(2):373-377$ .
- 472 2021;12(2):373-377.<br>473 Douglas, J.: Zhang, R
- 473 Douglas, J.; Zhang, R.; Bouckaert, R. Adaptive dating and fast proposals: Revisiting the phylogenetic relaxed clock model. PLoS Comput Biol. 2021 Feb:17(2):e1008322.
- 474 phylogenetic relaxed clock model. PLoS Comput Biol. 2021 Feb;17(2):e1008322.<br>475 Campbell. F.: Didelot. X.: Fitziohn. R.: Ferguson. N.: Cori. A.: Jombart. T. outbre
- 475 Campbell, F.; Didelot, X.; Fitzjohn, R.; Ferguson, N.; Cori, A.; Jombart, T. outbreaker2: a<br>476 modular platform for outbreak reconstruction. BMC Bioinformatics. 2018 Oct 22:19(Supp)
- 476 modular platform for outbreak reconstruction. BMC Bioinformatics. 2018 Oct 22;19(Suppl 477 11):363. 477 11):363.<br>478 HPSC. E
- 478 HPSC. Epidemiological characteristics of confirmed mpox cases in Ireland; May 2022 to<br>479 February 2023 Republic of Ireland: HPSC: [modified April 2023; cited 2023 28-07-2023]
- 479 February 2023 Republic of Ireland: HPSC; [modified April 2023; cited 2023 28-07-2023].<br>480 Available from:
- 480 Available from:<br>481 https://ndsc.new 481 https://ndsc.newsweaver.ie/4otaa688p3/18ojfxozmu1?lang=en&a=1&p=62869572&t=31302<br>482 978 482 978<br>483 Bab
- 483 Babkin, I.V.; Babkina, I.N.; Tikunova, N.V. An Update of Orthopoxvirus Molecular<br>484 Evolution. Viruses. 2022 Feb 14:14(2).
- 484 Evolution. Viruses. 2022 Feb 14;14(2).<br>485 HSE. Update on HSE monkeypox yacc
- 485 HSE. Update on HSE monkeypox vaccination programme; [cited 2023 2023-08-15].<br>486 Available from: https://www.hse.ie/eng/services/news/media/pressrel/update-on-hse-
- 486 Available from: https://www.hse.ie/eng/services/news/media/pressrel/update-on-hse-<br>487 monkeypox-vaccination-programme.html
- 487 monkeypox-vaccination-programme.html<br>488 Yang, S.: Guo, X.: Zhao, Z.: Abudunaibi.
- 488 Yang, S.; Guo, X.; Zhao, Z.; Abudunaibi, B.; Zhao, Y.; Rui, J.; Wang, Y.; Song, W.; Wei, H.; 489 Chen, T. Possibility of mpox viral transmission and control from high-risk to the general
- 489 Chen, T. Possibility of mpox viral transmission and control from high-risk to the general<br>490 population: a modeling study. BMC Infect Dis. 2023 Feb 24:23(1):119.
- 490 population: a modeling study. BMC Infect Dis. 2023 Feb 24;23(1):119.<br>491 Murphy. F. Mpox: China's health authorities fight surge in cases of unki
- 491 Murphy, F. Mpox: China's health authorities fight surge in cases of unknown origin. BMJ.<br>492 2023 Aug 22:382:1939.
- 492 2023 Aug 22;382:1939.<br>493 Mizushima, D.: Shintani
- 493 Mizushima, D.; Shintani, Y.; Takano, M.; Shiojiri, D.; Ando, N.; Aoki, T.; Watanabe, K.; 494 Nakamoto, T.; Gatanaga, H.; Oka, S. Prevalence of Asymptomatic Mpox among Men Wh
- 
- 494 Nakamoto, T.; Gatanaga, H.; Oka, S. Prevalence of Asymptomatic Mpox among Men Who<br>495 Have Sex with Men. Japan. January-March 2023. Emerging Infectious Diseases. 2023:29(9)
- 495 Have Sex with Men, Japan, January-March 2023. Emerging Infectious Diseases. 2023;29(9).<br>496 Isidro, J.: Borges, V.: Pinto, M.: Sobral, D.: Santos, J.D.: Nunes, A.: Mixao, V.: Ferreira, R.:
- 496 Isidro, J.; Borges, V.; Pinto, M.; Sobral, D.; Santos, J.D.; Nunes, A.; Mixao, V.; Ferreira, R.;<br>497 Santos, D.: Duarte, S.: Vieira, L.; Borrego, M.J.; Nuncio, S.; de Carvalho, I.L.; Pelerito, A.;
- 497 Santos, D.; Duarte, S.; Vieira, L.; Borrego, M.J.; Nuncio, S.; de Carvalho, I.L.; Pelerito, A.; 498 Cordeiro, R.; Gomes, J.P. Phylogenomic characterization and signs of microevolution in the
- 498 Cordeiro, R.; Gomes, J.P. Phylogenomic characterization and signs of microevolution in the 499 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022 Aug:28(8):1569-1572. 499 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022 Aug;28(8):1569-1572.<br>500 Yadav, P.; Devasurmutt, Y.; Tatu, U. Phylogenomic and Structural Analysis of the
- 500 Yadav, P.; Devasurmutt, Y.; Tatu, U. Phylogenomic and Structural Analysis of the 501 Monkeypox Virus Shows Evolution towards Increased Stability. Viruses. 2022 Dec
- 501 Monkeypox Virus Shows Evolution towards Increased Stability. Viruses. 2022 Dec 31;15(1).<br>502 Luna N: Ramirez AL: Munoz M: Ballesteros N: Patino L.H.: Castaneda S.A.: Bonilla-
- 502 Luna, N.; Ramirez, A.L.; Munoz, M.; Ballesteros, N.; Patino, L.H.; Castaneda, S.A.; Bonilla-<br>503 Aldana, D.K.: Paniz-Mondolfi, A.: Ramirez, J.D. Phylogenomic analysis of the monkeypox
- <sup>503</sup>Aldana, D.K.; Paniz-Mondolfi, A.; Ramirez, J.D. Phylogenomic analysis of the monkeypox

- 504 virus (MPXV) 2022 outbreak: Emergence of a novel viral lineage? Travel Med Infect Dis.<br>505 2022 Sep-Oct:49:102402.
- 505 2022 Sep-Oct;49:102402.<br>506 Mourier. T.: Sadykov. M.:
- 506 Mourier, T.; Sadykov, M.; Carr, M.J.; Gonzalez, G.; Hall, W.W.; Pain, A. Host-directed<br>507 editing of the SARS-CoV-2 genome. Biochem Biophys Res Commun. 2021 Jan 29:538:
- editing of the SARS-CoV-2 genome. Biochem Biophys Res Commun. 2021 Jan 29;538:35-39.
- 508<br>509 509 Lucey, M.; Macori, G.; Mullane, N.; Sutton-Fitzpatrick, U.; Gonzalez, G.; Coughlan, S.; 510 Purcell, A.; Fenelon, L.; Fanning, S.; Schaffer, K. Whole-genome Sequencing to Track
- 510 Purcell, A.; Fenelon, L.; Fanning, S.; Schaffer, K. Whole-genome Sequencing to Track<br>511 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in
- 511 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in<br>512 Nosocomial Outbreaks. Clin Infect Dis. 2021 Jun 1:72(11):e727-e735.
- 
- 512 Nosocomial Outbreaks. Clin Infect Dis. 2021 Jun 1;72(11):e727-e735.<br>513 Hare, D.; Gonzalez, G.; Dean, J.; McDonnell, K.; Carr, M.J.; De Gascu
- 513 Hare, D.; Gonzalez, G.; Dean, J.; McDonnell, K.; Carr, M.J.; De Gascun, C.F. Genomic<br>514 epidemiological analysis of SARS-CoV-2 household transmission. Access Microbiol. 514 epidemiological analysis of SARS-CoV-2 household transmission. Access Microbiol.<br>515 2021;3(7):000252.
- <sup>515</sup>2021;3(7):000252.